IBEX (IBEX) CFO reports 20,000-share grant and tax share withholding

Rhea-AI Filing Summary

IBEX Ltd's Chief Financial Officer, Taylor C. Greenwald, reported equity compensation activity involving the company’s common shares. On February 6, 2026, the CFO acquired 20,000 common shares at $0 per share as a restricted stock award tied to a May 31, 2024 performance share grant based on revenue and EBITDA targets.

On the same date, 2,121 common shares were disposed of at $34.98 per share to cover tax withholding upon vesting. After these transactions, the CFO directly beneficially owned 54,361 common shares. One-third of the performance-based shares vested on February 6, 2026, with additional one‑third tranches scheduled to vest on February 6, 2027 and February 6, 2028, subject to continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Greenwald Taylor C

(Last) (First) (Middle)

C/O IBEX LIMITED

1717 PENNSYLVANIA AVENUE NW, SUITE 825

(Street)

WASHINGTON DC 20006

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IBEX Ltd [ IBEX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/06/2026		A		20,000	A	$0(1)	56,482	D
Common Shares	02/06/2026		F		2,121(2)	D	$34.98	54,361	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reporting Person received this restricted stock award in connection with the vesting of a May 31, 2024 performance share award upon the attainment of certain Issuer Revenue and EBITDA targets for the trailing four (4) quarters. One-third of these shares vested on February 6, 2026. The remaining shares will vest one-third on February 6, 2027 and one-third on February 6, 2028. Vesting of performance share awards and shares issued in respect thereof is subject to the Reporting Person's continued service to the Company with Issuer through the applicable vesting date.

2. Represents shares withheld for tax purposes upon vesting of restricted stock grant.

Remarks:

	Lisa Lenstrohm, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did IBEX (IBEX) report for its CFO on February 6, 2026?

IBEX’s CFO, Taylor C. Greenwald, acquired 20,000 common shares as a restricted stock award and disposed of 2,121 shares to cover taxes. After these transactions, the CFO directly held 54,361 IBEX common shares, reflecting updated beneficial ownership.

How many IBEX (IBEX) shares does the CFO own after the latest Form 4 filing?

Following the reported transactions, IBEX’s CFO directly beneficially owns 54,361 common shares. This figure reflects the 20,000-share restricted stock award on February 6, 2026, net of 2,121 shares withheld and disposed of to satisfy tax obligations upon vesting.

What is the vesting schedule for the CFO’s IBEX (IBEX) performance-based restricted stock award?

The restricted stock award is linked to a May 31, 2024 performance share grant based on revenue and EBITDA targets. One-third vested on February 6, 2026, with additional one-third portions scheduled to vest on February 6, 2027 and February 6, 2028, subject to continued service.

Why were 2,121 IBEX (IBEX) shares disposed of in the CFO’s Form 4 filing?

The 2,121 IBEX common shares were withheld and disposed of at $34.98 per share to cover tax liabilities upon vesting of the restricted stock grant. This is a common mechanism to satisfy tax obligations without requiring separate cash payments.

What triggered the CFO’s restricted stock award reported by IBEX (IBEX)?

The restricted stock award was received upon vesting of a May 31, 2024 performance share award. Vesting was conditioned on achieving specified IBEX revenue and EBITDA targets over the trailing four quarters, and on the CFO’s continued service through each vesting date.

Is the IBEX (IBEX) CFO’s Form 4 transaction a market purchase or sale of shares?

The Form 4 shows an acquisition of 20,000 IBEX common shares as a grant at $0 per share, not an open-market purchase. The 2,121-share disposition reflects tax withholding on vesting, rather than a discretionary market sale by the CFO.